Actavis plc was a global pharmaceutical company focused on developing, manufacturing, and distributing generic, brand, and biosimilar products. Through a series of strategic acquisitions, including Warner Chilcott (2013) and Forest Laboratories (2014), Actavis grew significantly. In a transformative move in 2015, Actavis acquired Allergan, Inc. and subsequently adopted the Allergan name, becoming Allergan plc. Later, in 2016, Teva Pharmaceutical Industries acquired Allergan's global generics business (the former Actavis Generics). The remaining Allergan plc was then acquired by AbbVie in 2020. This page reflects information primarily about Actavis plc prior to its renaming and the divestiture of its generics arm.
Corporate headquarters for Actavis plc, overseeing global strategy, finance, legal operations, and governance.
Modern office facilities designed to support global executive functions and corporate governance for a multinational pharmaceutical company.
A dynamic, fast-paced, and growth-oriented environment, heavily influenced by frequent M&A activities and the integration of diverse company cultures. Strong emphasis on efficiency in generics and innovation in specialty pharmaceuticals.
The Irish domicile was strategically important for tax efficiency, global operational management, and access to European markets.
Historically, Actavis plc operated on a global scale, with a robust presence across North America, Europe, Asia-Pacific, and other regions. Its worldwide functions encompassed research and development centers, numerous manufacturing facilities, commercial sales and marketing offices, and extensive distribution networks. Actavis marketed its products in more than 60 countries, supporting both its extensive generic pharmaceuticals portfolio and its growing specialty branded business.
Clonshaugh Industrial Estate (historical administrative/operational base) / Corporate Domicile: 1 Grand Canal Square, Docklands (as it transitioned to Allergan plc)
Dublin
Dublin
Ireland
Address: Morris Corporate Center III, 400 Interpace Parkway, Parsippany, NJ 07054, USA (Historical U.S. Headquarters)
Key center for the North American market, housing significant leadership, drug development activities, and corporate support functions for many years.
Address: Reykjavíkurvegur 78, 220 Hafnarfjörður, Iceland (Historical)
Key manufacturing and development hub, particularly for European markets, and a link to the company's heritage.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Actavis (now Allergan)' leadership includes:
Actavis (now Allergan) has been backed by several prominent investors over the years, including:
The 2014-2015 period for Actavis was characterized by significant M&A activity, including the acquisition of Forest Laboratories and Allergan, Inc., leading to pivotal leadership appointments and transitions. These changes were instrumental in shaping the company's strategic direction and growth.
Discover the tools Actavis (now Allergan) uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
While Actavis as a standalone entity has been acquired and restructured (generics by Teva, remainder into Allergan then AbbVie), its historical email formats likely followed common corporate patterns. These domains (@actavis.com) are no longer actively used for the original company.
Common formats historically included: [first_initial][last]@actavis.com (e.g., jdoe@actavis.com) and [first].[last]@actavis.com (e.g., jane.doe@actavis.com).
Format
j.doe@actavis.com
Example
70%
Success rate
PR Newswire / Company Press Release (Archived) • March 17, 2015
Actavis plc announced it successfully completed its acquisition of Allergan, Inc. The combined company was renamed Allergan plc, creating a global pharmaceutical leader with expanded capabilities in brand development and generics....more
Company Press Release / FiercePharma (Archived reporting) • July 1, 2014
Actavis plc completed its $25 billion acquisition of Forest Laboratories. Brent Saunders, then CEO of Forest, was appointed CEO and President of the combined company, Actavis plc. Paul Bisaro, Actavis's then-CEO, became Executive Chairman....more
Teva Pharmaceutical Industries Press Release • August 2, 2016
Teva Pharmaceutical Industries Ltd. announced the completion of its acquisition of Allergan plc's global generics business (Actavis Generics). This acquisition significantly strengthened Teva's position as a global leader in generic pharmaceuticals....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Actavis (now Allergan), are just a search away.